Robocath, a Rouen, France-based medical robotics startup that designs and develops innovative solutions for the treatment of cardiovascular diseases, raised €4.7m ($5.2M) in funding.
The round was led by M Capital and Normandie Participations with participation from existing investors Go Capital and NCI.
The company, which had already raised a total of €1.8m ($2M) in 2013 and 2015, to which Bpifrance and others added €1.6m ($1.8M) of public aid, intends to use the funds for continued development.
Founded in 2009 by neuroradiologist Dr. Philippe Bencteux, chairman and founder, Robocath designs and develops robotic solutions to improve the management of the endovascular procedures performed in the treatment of cardiovascular diseases.
Currently at the manufacturing stage and in the process of obtaining the CE mark, the company’s first robotic platform, the R-one™, represents a major step forward in interventional cardiology. By improving patient care and reducing physicians’ exposure to X-rays, which currently cause some serious diseases, R-one benefits the whole health care system.
In practice, this integrated robotics platform covered by 20 families of international patents allows physicians to manage their instruments remotely from a control panel close to the operating table. It is a tool based on two major technologies:
– R-grasp®, which exactly reproduces hand movements (rotation and simultaneous movement), and
– SecurAccess®, which provides stability and security during the medical procedure.
The company employs around 20 staff.